Study of RC48 and carboplatin before surgery for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of the targeted therapy RC48 and the chemotherapy drug carboplatin given before surgery for people with advanced ovarian cancer that has a specific protein (HER2). The goal is to see if this treatment can shrink the tumor enough to allow for complete removal during surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with advanced (stage III or IV) high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Your tumor tests positive for the HER2 protein (at least 1+ on the test).
- Your cancer is not able to be completely removed with surgery at the time of diagnosis.
- You are in generally good health, with no severe heart, lung, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new targeted drug (distamab vedotin) combined with standard chemo (carboplatin) works better than chemo alone for women with advanced ovarian cancer that has high levels of HER2. It is for women who have not had chemotherapy yet and have already had surgery to remove the tumor.
This trial compares two chemotherapy drugs (paclitaxel alone vs. paclitaxel plus carboplatin) given before surgery for advanced ovarian cancer. It is specifically for people whose tumors have a high level of the PARK2 gene, which may make them respond better to one of the treatments.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.